Tetraphase Pharmaceuticals Inc. (TTPH)

1.30
0.04 2.99
NASDAQ : Health Technology
Prev Close 1.34
Open 1.34
Day Low/High 1.26 / 1.35
52 Wk Low/High 1.01 / 4.49
Volume 572.84K
Avg Volume 736.30K
Exchange NASDAQ
Shares Outstanding 53.74M
Market Cap 73.63M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
First Week of May 2018 Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week of May 2018 Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the May 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Tetraphase Pharmaceuticals Stock Sees Short Interest Increase 32.8%

Tetraphase Pharmaceuticals Stock Sees Short Interest Increase 32.8%

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 961,370 share increase in total short interest for Tetraphase Pharmaceuticals, Inc , to 3,889,264, an increase of 32.83% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Tetraphase Pharmaceuticals Announces Positive Phase 1 Single-Ascending Dose Data For Antibiotic Pipeline Candidates

Both TP-6076 and TP-271 Demonstrated Favorable Pharmacokinetic and Safety Profiles, Supporting Advancement into Multiple-Ascending Dose Studies

Tetraphase Pharmaceuticals' TP-6076 Selected By CARB-X To Receive $4 Million In Research Funding

Funding initiative focused on urgent public health crisis of antibiotic resistance

TTPH Crosses Above Average Analyst Target

In recent trading, shares of Tetraphase Pharmaceuticals, Inc have crossed above the average analyst 12-month target price of $8.40, changing hands for $8.67/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

First Week of August 18th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the August 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 186 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of May 2017 Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week of May 2017 Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the May 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 210 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D (Sell)